Amenorrhea as a rare drug-related adverse event associated with everolimus for pancreatic neuroendocrine tumors

被引:0
作者
Kawaguchi, Yoshiaki [1 ]
Maruno, Atsuko [1 ]
Kawashima, Yohei [1 ]
Ito, Hiroyuki [1 ]
Ogawa, Masami [1 ]
Mine, Tetsuya [1 ]
机构
[1] Tokai Univ, Dept Gastroenterol, Sch Med, Isehara, Kanagawa 2591193, Japan
关键词
Amenorrhea; Everolimus; Neuroendocrine tumor; Pancreas; Adverse event; TUBEROUS SCLEROSIS COMPLEX; CELL CARCINOMA; DOUBLE-BLIND; EFFICACY; TRIAL; MULTICENTER; OCTREOTIDE; RAPAMYCIN;
D O I
10.3748/wjg.v20.i42.15920
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
The patient was an asymptomatic 43-year-old woman. Abdominal ultrasonography and enhanced computed tomography showed a tumor lesion accompanied by multiple cystic changes in the liver and the pancreatic tail. Endoscopic ultrasound-fine needle aspiration was performed on the pancreatic tumor lesion and revealed pancreatic neuroendocrine tumor (PNET). As it was unresectable due to multiple liver metastases, the decision was made to initiate treatment with everolimus and transcatheter arterial chemoembolization. The patient ceased menstruating after the start of everolimus administration. When the administration was discontinued due to interstitial lung disease, menstruation resumed, but then again stopped with everolimus resumption. An association between everolimus and amenorrhea was highly suspected. Amenorrhea occurred as a rare adverse event of everolimus. As the younger women might be included in PNETs patients, we should put this adverse event into consideration. (C) 2014 Baishideng Publishing Group Inc. All rights reserved.
引用
收藏
页码:15920 / 15924
页数:5
相关论文
共 13 条
  • [1] Everolimus for angiomyolipoma associated with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis (EXIST-2): a multicentre, randomised, double-blind, placebo-controlled trial
    Bissler, John J.
    Kingswood, J. Christopher
    Radzikowska, Elzbieta
    Zonnenberg, Bernard A.
    Frost, Michael
    Belousova, Elena
    Sauter, Matthias
    Nonomura, Norio
    Brakemeier, Susanne
    de Vries, Petrus J.
    Whittemore, Vicky H.
    Chen, David
    Sahmoud, Tarek
    Shah, Gaurav
    Lincy, Jeremie
    Lebwohl, David
    Budde, Klemens
    [J]. LANCET, 2013, 381 (9869) : 817 - 824
  • [2] Efficacy and safety of everolimus for subependymal giant cell astrocytomas associated with tuberous sclerosis complex (EXIST-1): a multicentre, randomised, placebo-controlled phase 3 trial
    Franz, David Neal
    Belousova, Elena
    Sparagana, Steven
    Bebin, E. Martina
    Frost, Michael
    Kuperman, Rachel
    Witt, Olaf
    Kohrman, Michael H.
    Flamini, J. Robert
    Wu, Joyce Y.
    Curatolo, Paolo
    de Vries, Petrus J.
    Whittemore, Vicky H.
    Thiele, Elizabeth A.
    Ford, James P.
    Shah, Gaurav
    Cauwel, Helene
    Lebwohl, David
    Sahmoud, Tarek
    Jozwiak, Sergiusz
    [J]. LANCET, 2013, 381 (9861) : 125 - 132
  • [3] Pancreatic Endocrine Tumors: Expression Profiling Evidences a Role for AKT-mTOR Pathway
    Missiaglia, Edoardo
    Dalai, Irene
    Barbi, Stefano
    Beghelli, Stefania
    Falconi, Massimo
    della Peruta, Marco
    Piemonti, Lorenzo
    Capurso, Gabriele
    Di Florio, Alessia
    delle Fave, Gianfranco
    Pederzoli, Paolo
    Croce, Carlo M.
    Scarpa, Aldo
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (02) : 245 - 255
  • [4] Antitumor activity of rapamycin and octreotide as single agents or in combination in neuroendocrine tumors
    Moreno, Amy
    Akcakanat, Argun
    Munsell, Mark F.
    Soni, Alpana
    Yao, James C.
    Meric-Bemstam, Funda
    [J]. ENDOCRINE-RELATED CANCER, 2008, 15 (01) : 257 - 266
  • [5] Efficacy of everolimus in advanced renal cell carcinoma:: a double-blind, randomised, placebo-controlled phase III trial
    Motzer, Robert J.
    Escudier, Bernard
    Oudard, Stephane
    Hutson, Thomas E.
    Porta, Camillo
    Bracarda, Sergio
    Gruenwald, Viktor
    Thompson, John A.
    Figlin, Robert A.
    Hollaender, Norbert
    Urbanowitz, Gladys
    Berg, William J.
    Kay, Andrea
    Lebwohl, David
    Ravaud, Alain
    [J]. LANCET, 2008, 372 (9637) : 449 - 456
  • [6] Phase I pharmacokinetic and pharmacodynamic study of the oral mammalian target of rapamycin inhibitor everolimus in patients with advanced solid tumors
    O'Donnell, Anne
    Faivre, Sandrine
    Burris, Howard A., III
    Rea, Daniel
    Papadimitrakopoulou, Vassiliki
    Shand, Nicholas
    Lane, Heidi A.
    Hazell, Katharine
    Zoellner, Ulrike
    Kovarik, John M.
    Brock, Cathryn
    Jones, Suzanne
    Raymond, Eric
    Judson, Ian
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (10) : 1588 - 1595
  • [7] Sunitinib Malate for the Treatment of Pancreatic Neuroendocrine Tumors.
    Raymond, Eric
    Dahan, Laetitia
    Raoul, Jean-Luc
    Bang, Yung-Jue
    Borbath, Ivan
    Lombard-Bohas, Catherine
    Valle, Juan
    Metrakos, Peter
    Smith, Denis
    Vinik, Aaron
    Chen, Jen-Shi
    Hoersch, Dieter
    Hammel, Pascal
    Wiedenmann, Bertram
    Van Cutsem, Eric
    Patyna, Shem
    Lu, Dongrui Ray
    Blanckmeister, Carolyn
    Chao, Richard
    Ruszniewski, Philippe
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2011, 364 (06) : 501 - 513
  • [8] von Wichert G, 2000, CANCER RES, V60, P4573
  • [9] Efficacy of RAD001 (everolimus) and octreotide LAR in advanced low- to intermediate-grade neuroendocrine tumors: Results of a phase II study
    Yao, James C.
    Phan, Alexandria T.
    Chang, David Z.
    Wolff, Robert A.
    Hess, Kenneth
    Gupta, Sanjay
    Jacobs, Carmen
    Mares, Jeannette E.
    Landgraf, Andrea N.
    Rashid, Asif
    Meric-Bernstam, Funda
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (26) : 4311 - 4318
  • [10] One hundred years after "Carcinoid": Epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States
    Yao, James C.
    Hassan, Manal
    Phan, Alexandria
    Dagohoy, Cecile
    Leary, Colleen
    Mares, Jeannette E.
    Abdalla, Eddie K.
    Fleming, Jason B.
    Vauthey, Jean-Nicolas
    Rashid, Asif
    Evans, Douglas B.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (18) : 3063 - 3072